A PHASE I-III, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS, WITH LOCALLY ADVANCED, UNRESECTABLE, STAGE III NON-SMALL CELL LUNG CANCER (BO42777)
Principal Investigator
Timothy A. McCarthy, MDLocations
Fairfax Office
Arlington Office
Gainesville Office
Loudoun Office
Alexandria Office
Learn More About This Trial
Other Relevant Trials
A Phase 3, Open-label, Randomized Study of Lazertinib with Subcutaneous Amivantamab Administered via Manual Injection Compared with Intravenous Amivantamab or Amivantamab Subcutaneous On Body Delivery System in Patients with EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer After Progression on Osimertinib and Chemotherapy
Principal Investigator
Alexander I. Spira, MD, PhD, FACPA PHASE 1B/2 STUDY OF TPX-0022 IN COMBINATION WITH EQ143 IN NON-SMALL CELL LUNG CANCER SUBJECTS